Bethel M Angelyn, Feinglos Mark N
Department of Medicine, Box 3921, Duke University Medical Center, Durham, NC 27710, USA.
Curr Diab Rep. 2002 Oct;2(5):403-8. doi: 10.1007/s11892-002-0104-4.
Insulin therapy is ultimately necessary for the control of blood glucose in a majority of patients with type 2 diabetes mellitus. Unfortunately, the pharmacokinetic characteristics of previously available rapid-, intermediate-, and long-acting preparations make sustained normoglycemia almost impossible. Advances in molecular genetic engineering have made possible the development of insulin analogues with pharmacokinetics that more closely mimic the needs of patients with type 2 diabetes. In the following article, we explore the insulin analogues currently available for clinical use, their pharmacokinetics, and the rationale for their use in the treatment of type 2 diabetes, and follow-up with a brief examination of future developments.
对于大多数2型糖尿病患者而言，胰岛素治疗最终是控制血糖所必需的。不幸的是，先前可用的速效、中效和长效制剂的药代动力学特性使得持续正常血糖几乎无法实现。分子基因工程的进展使得开发药代动力学更能紧密模拟2型糖尿病患者需求的胰岛素类似物成为可能。在接下来的文章中，我们将探讨目前可用于临床的胰岛素类似物、它们的药代动力学以及在2型糖尿病治疗中使用它们的基本原理，并简要考察未来的发展情况。
